Both Semaglutide and Terzepitide have brand name version of the drug that are FDA approved for treatment of DM-2. Semaglutide has Ozempic and Terzepitide has Mounjaro brand names approved. Each drug also has a brand name approved specifically for weight loss; Semaglutide has Wegovy and Terzepitide has Zepbound brand names.

Clients with DM-2 can improve glycemic control and reduce the risk of major cardiovascular events with the use of GLP-1 agonists. They will lower blood glucose levels, hemoglobin A1c level, and reduce body weight.

There is a risk of hypoglycemia when combining GLP-1 agonists with other diabetes medications such as insulin or sulfonylureas like Glipizide or Glyburide.